{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:05:45Z","timestamp":1791655545018,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.jaad.2016.01.019","type":"journal-article","created":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T10:36:09Z","timestamp":1457174169000},"page":"1077-1085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial"],"prefix":"10.1016","volume":"74","author":[{"given":"Ga\u00ebl","family":"Deplanque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radj","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Vergnenegre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Falchero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Jean","family":"Souquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Chavaillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Taviot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghislaine","family":"Fraboulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"Saal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chosidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2016.01.019_bib1","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1200\/JCO.2009.23.5622","article-title":"American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer","volume":"27","author":"Azzoli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2016.01.019_bib2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/annonc\/mdp132","article-title":"Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"D'Addario","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2016.01.019_bib3","unstructured":"Tarceva [summary of product characteristics]. Basel, Switzerland: Roche. 2010."},{"key":"10.1016\/j.jaad.2016.01.019_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2016.01.019_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, randomized phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2016.01.019_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomized, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2016.01.019_bib7","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2006.05.8073","article-title":"Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21","volume":"24","author":"Bezjak","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2016.01.019_bib8","first-page":"211","article-title":"Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis","volume":"7","author":"Jia","year":"2009","journal-title":"J Support Oncol"},{"key":"10.1016\/j.jaad.2016.01.019_bib9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaad.2016.01.019_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.lungcan.2015.03.019","article-title":"Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients","volume":"88","author":"Arrieta","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jaad.2016.01.019_bib11","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/JTO.0b013e3181e981d9","article-title":"Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer","volume":"5","author":"Becker","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jaad.2016.01.019_bib12","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2016.01.019_bib13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","article-title":"Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)","volume":"113","author":"Jatoi","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2016.01.019_bib14","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2016.01.019_bib15","first-page":"5S","article-title":"Pan-Canadian rash trial with EGFR inhibitors (abstract 8013)","volume":"32","author":"Melosky","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2016.01.019_bib16","unstructured":"National Cancer Institute, US Department of Health and Human Services, National Institutes of Health. Common Terminology Criteria for Adverse Events. Available from: URL: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE. Accessed January 2016."},{"key":"10.1016\/j.jaad.2016.01.019_bib17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2016.01.019_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jaad.2016.01.019_bib19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2016.01.019_bib20","first-page":"1079","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2016.01.019_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-009-0114-0","article-title":"Skin toxicities associated with epidermal growth factor receptor inhibitors","volume":"4","author":"Li","year":"2009","journal-title":"Target Oncol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216000682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216000682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:39:20Z","timestamp":1759271960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216000682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0190962216000682"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.01.019","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}